IBI345

IBI345 is a universal, modular chimeric antigen receptor T (CAR-T) cell therapy designed to target Claudin 18.2 (CLDN18.2), a tumor-associated antigen highly expressed in certain solid tumors. The product consists of two components: an anti-Claudin18.2 antibody that recognizes and binds the tumor antigen, and modular CAR-T cells that are activated upon engagement with the antibody-antigen complex[1][3][8]. This design allows for precise targeting and regulation of CAR-T cell activity, potentially improving safety by controlling expansion and enabling switching to other antibodies for different antigens if needed[3]. Developed by Innovent Biologics using technology from Roche, IBI345 is being investigated primarily for CLDN18.2-positive solid tumors such as gastric cancer[3][4][8].

Other names

anti-Claudin18.2 CAR T cellsanti-Claudin-18.2 CAR T cellsanti-Claudin 18.2 CAR T cells